Biological agents improve disease control, visual acuity in eyes with refractory, active NIPPU
Use of biologic agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis or panuveitis (NIPPU) is associated with satisfactory disease control, reduced use of systemic immunosuppression, stable visual acuity and a 23.7-percent risk of disease relapse, reveals a study.
